GSK dumps Adolor; Pfizer releases study findings;

> We all know that severe depression can increase suicidal ideation and behaviors, but things get extremely confusing when the drugs used to treat depression might raise the suicide risk, too. Report

> GlaxoSmithKline has been working with Adolor on a development deal for Entereg, a drug to treat chronic opiod bowel dysfunction caused by long-term use of pain medications, but the two companies have decided to part ways. Report

> Not just for old men: a popular drug used to help men in the bedroom is keeping a seven-year-old girl with primary pulmonary hypertension alive.  Report

> Boston Scientific's released study data for its drug-coated stent, Taxus Liberte - which the FDA has yet to approve in the U.S. - based on patients in 57 countries. Report

> Shionogi has joined a lineup of Japanese pharma companies turning to buyouts as a central method for diversifying their companies and prospects. Shionogi is paying $1.4 billion to buy Atlanta-based Sciele Pharma. Report

> Pfizer Inc. and Bristol-Myers Squibb Co. released safety study findings about their experimental blood thinner, apixaban, saying that it might reduce acute coronary symptoms and the risk of a second heart attack, stroke or death. Report

> The NIH has earmarked $280 million over the next four years for nine institutions involved in small molecule screening programs to advance the use of chemical probes in researching new medicines. Report

> Australian transplant Peplin has rounded up $24 million and two new top executives. New Enterprise Associates, MPM Capital, and two Australian investors put up the money. Report

> Palo Alto may have to say goodbye to as many as 3,000 jobs. According to the San Francisco Business Times, Roche is planning to move its inflammation business from Palo Alto to Nutley, NJ and its virology ops--also at Palo Alto--to South San Francisco. Report

> Shares of Introgen Therapeutics plunged 26 percent this morning after investors learned that the FDA has rejected its BLA for the cancer therapy Advexin. Report 

> Noted UK biotech investor Sir Christopher Evans has analyzed what ails the country's development business and has come up with a cure. Report

> By studying the victims of a rare genetic disease, NIH researchers have highlighted the role that brain-derived neurotrophic factor--a chemical made in the brain--has on promoting obesity. Report

> A sophisticated new approach to using single-nucleotide polymorphisms, or SNPs, to identify people has raised concerns over the privacy of people who volunteer for genetic research. Report

> Big Pharma is going back to college. With analysts eager to highlight the deficiencies of their pipelines, major companies like GlaxoSmithKline, AstraZeneca and Pfizer have been signing up with academic researchers to explore new avenues of drug development. Report

And Finally... What does the pharmaceutical industry have in common with the entertainment industry? Size, speed, scarcity, sustainability and sizzle, one Business Week writer says. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.